JPWO2020260897A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020260897A5 JPWO2020260897A5 JP2021577431A JP2021577431A JPWO2020260897A5 JP WO2020260897 A5 JPWO2020260897 A5 JP WO2020260897A5 JP 2021577431 A JP2021577431 A JP 2021577431A JP 2021577431 A JP2021577431 A JP 2021577431A JP WO2020260897 A5 JPWO2020260897 A5 JP WO2020260897A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- sequence
- cell
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183318 | 2019-06-28 | ||
| EP19183318.5 | 2019-06-28 | ||
| EP20170163 | 2020-04-17 | ||
| EP20170163.8 | 2020-04-17 | ||
| PCT/GB2020/051557 WO2020260897A1 (en) | 2019-06-28 | 2020-06-26 | Novel cancer antigens and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539157A JP2022539157A (ja) | 2022-09-07 |
| JPWO2020260897A5 true JPWO2020260897A5 (https=) | 2023-07-05 |
| JP2022539157A5 JP2022539157A5 (https=) | 2023-07-05 |
Family
ID=71266763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577431A Pending JP2022539157A (ja) | 2019-06-28 | 2020-06-26 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220220175A1 (https=) |
| EP (1) | EP3990006A1 (https=) |
| JP (1) | JP2022539157A (https=) |
| KR (1) | KR20220029561A (https=) |
| CN (1) | CN114341169B (https=) |
| AU (1) | AU2020302285A1 (https=) |
| BR (1) | BR112021026364A2 (https=) |
| CA (1) | CA3141553A1 (https=) |
| IL (1) | IL289200A (https=) |
| MX (1) | MX2021015765A (https=) |
| WO (1) | WO2020260897A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| CN116057067A (zh) * | 2020-04-17 | 2023-05-02 | 弗朗西斯·克里克研究所有限公司 | 用于治疗黑素瘤的ctl抗原的融合蛋白 |
| JP2023522193A (ja) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 抗原プール |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515734A (ja) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| JP2003304877A (ja) * | 2002-04-15 | 2003-10-28 | Keio Gijuku | ヒト色素細胞特異分子 |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| KR20180135481A (ko) * | 2016-04-21 | 2018-12-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 흑색종 및 기타 암에 대한 면역요법 |
| KR20210086612A (ko) * | 2018-09-04 | 2021-07-08 | 트레오스 바이오 리미티드 | 펩타이드 백신 |
| BR112021006941A2 (pt) * | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
-
2020
- 2020-06-26 AU AU2020302285A patent/AU2020302285A1/en not_active Abandoned
- 2020-06-26 CA CA3141553A patent/CA3141553A1/en active Pending
- 2020-06-26 EP EP20735233.7A patent/EP3990006A1/en active Pending
- 2020-06-26 KR KR1020217039990A patent/KR20220029561A/ko not_active Ceased
- 2020-06-26 CN CN202080047510.8A patent/CN114341169B/zh active Active
- 2020-06-26 WO PCT/GB2020/051557 patent/WO2020260897A1/en not_active Ceased
- 2020-06-26 JP JP2021577431A patent/JP2022539157A/ja active Pending
- 2020-06-26 BR BR112021026364A patent/BR112021026364A2/pt not_active IP Right Cessation
- 2020-06-26 MX MX2021015765A patent/MX2021015765A/es unknown
-
2021
- 2021-12-17 US US17/644,928 patent/US20220220175A1/en active Pending
- 2021-12-21 IL IL289200A patent/IL289200A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Cancer vaccines as promising immuno-therapeutics: platforms and current progress | |
| Molino et al. | Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses | |
| Neek et al. | Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses | |
| JP5127224B2 (ja) | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 | |
| JP5239041B2 (ja) | 癌の治療剤 | |
| JP6945301B2 (ja) | Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン | |
| Saenz‐Badillos et al. | RNA as a tumor vaccine: a review of the literature | |
| CN115845040A (zh) | 用于免疫疗法的核/壳结构平台 | |
| JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 | |
| JP2006523688A (ja) | ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット | |
| JP7116278B2 (ja) | 癌治療のための免疫原性化合物 | |
| JP2001509490A (ja) | Ｃｔｌ応答を誘導する方法 | |
| JP2016501829A (ja) | 細胞透過性ペプチド | |
| ES2900262T3 (es) | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular | |
| CN108743937A (zh) | 疫苗组合物和方法 | |
| CN101146550A (zh) | 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法 | |
| Kikuchi | Genetically modified dendritic cells for therapeutic immunity | |
| Wu et al. | Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors | |
| JP2011506497A5 (https=) | ||
| CN107286244B (zh) | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 | |
| JPWO2020260897A5 (https=) | ||
| Errington et al. | Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. | |
| JPWO2021005338A5 (https=) | ||
| JPWO2021005339A5 (https=) | ||
| JPWO2020079448A5 (https=) |